Literature DB >> 10102478

Utilization of previously treated patients (PTPs), noninfected patients (NIPs), and previously untreated patients (PUPs) in the evaluation of new factor VIII and factor IX concentrates. Recommendation of the Scientific Subcommittee on Factor VIII and Factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis.

G C White, D DiMichele, K Mertens, C Negrier, I R Peake, C Prowse, R Schwaab, A Yoshioka, J Ingerslev.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10102478

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN： 0340-6245            Impact factor:   5.249


× No keyword cloud information.
  11 in total

Review 1.  Inhibitors in previously treated patients: a review of the literature.

Authors:  C L Kempton
Journal:  Haemophilia       Date:  2010-05       Impact factor: 4.287

2.  Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy.

Authors:  Angiola Rocino; Antonio Coppola; Massimo Franchini; Giancarlo Castaman; Cristina Santoro; Ezio Zanon; Elena Santagostino; Massimo Morfini
Journal:  Blood Transfus       Date:  2014-10       Impact factor: 3.443

Review 3.  Alloantibodies to therapeutic factor VIII in hemophilia A: the role of von Willebrand factor in regulating factor VIII immunogenicity.

Authors:  Johannes Oldenburg; Sébastien Lacroix-Desmazes; David Lillicrap
Journal:  Haematologica       Date:  2015-02       Impact factor: 9.941

Review 4.  Evolution of recombinant factor VIII safety: KOGENATE and Kogenate FS/Bayer.

Authors:  Jeanne M Lusher; Inge Scharrer
Journal:  Int J Hematol       Date:  2009-11-03       Impact factor: 2.490

Review 5.  How do we optimally utilize factor concentrates in persons with hemophilia?

Authors:  Ming Y Lim
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

Review 6.  Management of haemophilia A-inhibitor patients: clinical and regulatory perspectives.

Authors:  Zera Tellier; Marie-Hélène André; Benoît Polack
Journal:  Clin Rev Allergy Immunol       Date:  2009-10       Impact factor: 8.667

Review 7.  Factor VIII inhibitors: risk factors and methods for prevention and immune modulation.

Authors:  Ai Hong Zhang; Jonathan Skupsky; David W Scott
Journal:  Clin Rev Allergy Immunol       Date:  2009-10       Impact factor: 8.667

8.  Experience of Advate rAHF-PFM in previously untreated patients and minimally treated patients with haemophilia A.

Authors:  Guenter Auerswald; Alexis A Thompson; Michael Recht; Deborah Brown; Raina Liesner; Norma Guzmán-Becerra; Jacqueline Dyck-Jones; Bruce Ewenstein; Brigitt Abbuehl
Journal:  Thromb Haemost       Date:  2012-04-04       Impact factor: 5.249

9.  The prevalence and risk factors of inhibitor development of FVIII in previously treated patients with hemophilia A.

Authors:  Ju Young Kim; Chur Woo You
Journal:  Blood Res       Date:  2019-09-25

Review 10.  Anti-hemophilic factor (recombinant), plasma/albumin-free method (octocog-alpha; ADVATE) in the management of hemophilia A.

Authors:  Amy D Shapiro
Journal:  Vasc Health Risk Manag       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.